Related Experiment Videos
Novel therapies for chronic myelogenous leukemia
B N Jahagirdar1, J S Miller, A Shet
1Stem Cell Institute, Division of Hematology-Oncology and Transplantation, University of Minnesota, Minneapolis, Minn 55455, USA.
Abstract:
The BCR-ABL oncogene is essential to the pathogenesis of chronic myelogenous leukemia, and immune mechanisms play an important role in control of this disease. Understanding of the molecular pathogenesis of chronic myelogenous leukemia has led to the development of several novel therapies, which can be broadly divided into therapies based on 1) inhibition of the BCR-ABL oncogene expression, 2) inhibition of other genes important to the pathogenesis of chronic myelogenous leukemia, 3) inhibition of BCR-ABL protein function, and 4) immunomodulation. We have systematically reviewed each of these novel therapeutic approaches in this article.